Mon, May 17, 2010
Sun, May 16, 2010
Sat, May 15, 2010
Fri, May 14, 2010
Thu, May 13, 2010
Wed, May 12, 2010
[ Wed, May 12th 2010 ] - Market Wire
ENVIROTEK Becomes "SUFFER"
Tue, May 11, 2010
Mon, May 10, 2010
Sun, May 9, 2010
Sat, May 8, 2010
Fri, May 7, 2010
Thu, May 6, 2010
Mon, January 11, 2010
Sat, January 9, 2010
Fri, January 8, 2010
Thu, January 7, 2010
Wed, January 6, 2010
Tue, January 5, 2010

SciClone Pharmaceuticals to Present at Two Investor Conferences in May


//health-fitness.news-articles.net/content/2010/ .. -present-at-two-investor-conferences-in-may.html
Published in Health and Fitness on Monday, May 10th 2010 at 15:40 GMT by Market Wire   Print publication without navigation


FOSTER CITY, CA--(Marketwire - May 10, 2010) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it will present at two upcoming investor conferences: Rodman & Renshaw Annual London Investment China Conference, and the Oppenheimer Annual China Dragon Call Conference. SciClone's executives will present a corporate overview and business update at each conference.

Rodman & Renshaw Annual London Investment Conference
Monday, May 17; 4:05 pm GMT
London, UK
Presenter: Friedhelm Blobel, Ph.D., President and CEO
Webcast: To access the live audio webcasts of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at [ www.sciclone.com ].
Oppenheimer Annual China Dragon Call Conference
Tuesday, May 18; 4:40 pm ET
New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO
Presentations made at this conference are not being webcast.

About SciClone
SciClone Pharmaceuticals (NASDAQ: [ SCLN ]) is a profit-focused, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China, including Hong Kong and Macau, and Vietnam, for which it will seek regulatory approval. For additional information, please visit [ www.sciclone.com ].


Publication Contributing Sources